A single immunization with cellular vaccine confers dual protection against SARS‐CoV‐2 and cancer

The efficacy of current coronavirus disease 2019 (COVID‐19) vaccines has been demonstrated; however, emerging evidence suggests insufficient protection in certain immunocompromised cancer patients. We previously developed a cell‐based anti‐cancer vaccine platform involving artificial adjuvant vector...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Kanako, Ueda, Shogo, Kawamura, Masami, Satoh, Mikiko, Fujii, Shin‐ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348309/
https://www.ncbi.nlm.nih.gov/pubmed/35598170
http://dx.doi.org/10.1111/cas.15434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348309/
https://www.ncbi.nlm.nih.gov/pubmed/35598170
http://dx.doi.org/10.1111/cas.15434

Ejemplares similares